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Sialadenitis, inflammation of a salivary gland,
typically presents with pain, swelling, and erythema
of the oral mucosa. In particular, lymphocytic
sialadenitis is most commonly associated with
Sj€ogren’s syndrome and hepatitis C viral infection
but has never been described in the setting of
interleukin (IL)-17 inhibition. We report a case of
lymphocytic sialadenitis in the setting of ixekizumab
treatment for psoriasis.Fig 1. Oral mucosa shows multiple erosions and vesicles
with underlying background erythema. The hard and soft
palate, gingivae, and lips were primarily involved.CASE REPORT
A 25-year-old man with a medical history of
psoriasis presented to the University hospital
complaining of severe pain associated with oral
ulcers and difficulty swallowing. The ulcers
developed 1 week before presentation. His primary
care physician prescribed valacyclovir, prednisone,
and viscous lidocaine without improvement. The
patient reported being enrolled in a clinical trial for
psoriasis. Chronic plaque psoriasis was diagnosed
8 years prior, which was treated with ustekinumab
with significant but incomplete improvement. He
started the trial several months before presentation.
The patient reported no other recent medication
changes and felt well until the development of the
ulcers. On examination, the oral mucosa showed
multiple erosions and vesicles with underlying
background erythema. The hard and soft palate,
gingivae, and lips were primarily involved (Fig 1).
Over the next 24 hours, the patient became febrile,
and erythematous tender nodules developed on the
extensor surfaces of the legs and distal upperthe College of Medicinea and the Departments of Derma-
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consistent with those of erythema nodosum.
Contact with the unblinded clinical trial adminis-
trator found that the patient was receiving the active
agent, ixekizumab, an IL-17 inhibitor, and not
placebo. A biopsy of the mucosal upper lip found a
dense lymphoplasmacytic infiltrate surrounding the
minor salivary glands and the salivary duct with
mucositis and surface ulceration (Fig 2). Direct
immunofluorescence findings were negative. A
biopsy of the lower extremity found an early septal
panniculitis consistent with the clinical impression of
erythema nodosum. Laboratory workup findingsJAAD Case Reports 2016;2:92-4.
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Fig 2. Punch biopsy results show a dense lymphoplasmacytic infiltrate surrounding the minor
salivary glands and the salivary duct with mucositis and surface ulceration of the upper lip.
Table I. Adverse events associated with ixekizumab
treatment in phase II clinical trials3
Nasopharyngitis
Injection site reaction
Elevation of creatine kinase
Grade II neutropenia
Peripheral edema*
Urticaria*
Upper respiratory infection
Headache
Elevation of liver transaminases
Minor infections
Hypersensitivity*
*Patient discontinued trial because of adverse event.
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transaminase (87), alanine transaminase (105), eryth-
rocyte sedimentation rate (30), and C-reactive
protein (29). Findings were negative for rapid
plasma reagin, cytomegalovirus serology, viral
cultures, human immunodeficiency virus, antistrep-
tolysin O antigen, and hepatitis panel. The patient
was started on methylprednisolone and converted to
an oral steroid taper and showed marked improve-
ment. He was discharged after a 3-day admission.
DISCUSSION
Recent evidence suggests that psoriasis is depen-
dent on T helper 17 (Th17) cells. In peripheral
tissues, Th17 cells develop after exposure to trans-
forming growth factor beta 1 and IL-6 and are
sustained by IL-23, produced by both keratinocytes
and dendritic cells. Th17 cells produce and secrete a
variety of proinflammatory cytokines, most notablyIL-17 and IL-22. IL-17 is mainly involved in the
recruitment and activation of neutrophils and is
able to directly inhibit apoptosis of neutrophils in
inflamed tissues. IL-22 is responsible for keratinocyte
hyperproliferation.1 The efficacy of ustekinumab, a
monoclonal antibody directed against IL-12 and
IL-23, further supports the role of Th17 cells.2
In a phase II trial of ixekizumab, no serious
adverse events (SAEs) were reported, but there
were several mild adverse events including injec-
tion site reactions, nasopharyngitis, upper respira-
tory infection, and headache (Table I).3 In another
phase II trial of ixekizumab, there were 15 SAEs
reported in 10 (8%) patients (Table II), none that
were major cardiac events.4 Among both of these
studies, neither sialadenitis nor erythema nodosum
was reported.
Lymphocytic sialadenitis can be present in both
Sj€ogren’s syndrome and hepatitis C viral infection but
has not been reported in association with IL-17
inhibition. In patients with annular erythema
associated with Sj€ogren’s syndrome, IL-17 producing
Th17 cells and regulatory T cells are found to play a
role in maintaining mucoepithelitis. The pattern of
infiltration observed among patients with annular
erythema associated with Sj€ogren’s syndrome
compared with other Th17 cellemediated diseases,
such as systemic lupus erythematous, atopic
dermatitis, and psoriasis, was found to be unique,
as dense dermal infiltrates are seen as opposed to
superficial infiltration.5 Compared with this case,
however, the clinical and histologic presentations do
not fit that of Sj€ogren’s syndrome or hepatitis C virus
infection.6-8 This case shows an unusual and not
previously reported side effect of IL-17 inhibition.
Table II. Serious adverse events associated with
ixekizumab treatment in phase II clinical trials4
Rectal cancer
Depression
Atherosclerosis
Urinary tract infection
Pyelonephritis
Nephrolithiasis
Laceration of the left arm
Exacerbation of hidradenitis suppurativa
Suicide attempt
Congestive heart failure
Cellulitis
Acute coronary syndrome
Wrist fracture
None of these SAEs were major cardiac events.
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were not found, and the degree of symptomatology
was striking compared with other causes of
sialadenitis. The response to systemic glucocorti-
coids was rapid.
CONCLUSION
As the use IL-17 inhibitors becomes more wide-
spread in the treatment of plaque psoriasis, clinicians
need to be aware of unusual side effects not previ-
ously described in clinical trials. Although headache,
injection site reaction, nasopharyngitis, and upper
respiratory infection seem to most commonly result,other adverse reactions can include neutropenia,
elevation of liver transaminase levels, sialadenitis,
and erythema nodosum. Vigilant monitoring of
patients receiving this novel drug is warranted to
assess for unusual reactions, as this highly efficacious
biologic is adapted into clinical use.
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